NTGN News and Press, Neon Therapeutics Inc. From 03/04/19

CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Cowen and C...

CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, t...

CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the 8th Annual L...

CORAL GABLES, FL / ACCESSWIRE / February 6, 2019 / The biotech stock market has always been a sector replete with innovation, and conversation surrounding companies looking into nuanced approaches to designing effective treatment options for patients suffering a wide array of diseases. Acc...

Gainers:  MacroGenics (NASDAQ: MGNX ) +129% . Snap (NYSE: SNAP ) +24% . Jason Industries (NASDAQ: JASN ) +23% . Bionano Genomics (NASDAQ: BNGO ) +16% . Proteostasis Therapeutics (NASDAQ: PTI ) +16% . Plantronics (NYSE: PLT ) +15% . Neon Therapeutics (NASDAQ: NTGN ) +15% . MaxLi...